CClinicalTrials.gg
CompletedNCT03274232Updated Sep 6, 2017

Face Photoaging: Efficacy and Tolerance Evaluation of an Intradermal Injective Treatment

An interventional study of SUNEKOS ® 200 in Face Skin Photoaging, sponsored by Derming SRL. Completed. Open to female participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Derming SRL · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
25
Allocation
Not applicable
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

Efficacy and tolerance evaluation of an intradermal injective treatment

Read the detailed description

Primary end point of the study was to evaluate clinically and by non-invasive instrumental evaluations tolerance and efficacy of SUNEKOS ® 200 injectable treatment on main sign of face skin photoaging; the micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade.

02

Conditions studied

  • Face Skin Photoaging

Browse trials for

03

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

    • female sex;
  • age 45-65 years;
  • mild/moderate cutaneous photoaging according to a reference photographic scale (see Appendix 8)
  • skin phototype I, II and III according to Fitzpatrick's classification, with a preference to grade II-III (see par. 8.1)
  • agreeing to present at each study visit without make-up;
  • accepting to not change their habits regarding food, physical activity, make-up use, face cosmetic and cleansing products;
  • accepting not to expose their face to strong UV irradiation (UV session, or sun bathes), during the entire duration of the study;
  • accepting to sign the Informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Dependent on the volunteers' characteristics
  • Pregnancy;
  • lactation;
  • subjects not in menopause who do not use adequate contraceptive precautions in order to avoid pregnancies during the study;
  • Body Mass Index (BMI) variation (± 1) during the study period;
  • subjects not in menopause who do not accept to perform the pregnancy test during the basal visit, 30 days (T4i) and 2 months (T2M) after the first biomineralizing treatment execution;
  • performing skin treatments for aesthetic correction (biomaterials implants, face lifting, botox injections, laser, chemical peeling) in the 12 months prior to the study start;
  • performing permanent filler in the past;
  • change in the normal habits regarding food, physical activity, face cosmetic, cleansing and make-up use during the month preceding the test;
  • sensitivity to the test product or its ingredients (to be assessed by the investigator during the baseline visit);
  • subjects whose insufficient adhesion to the study protocol is foreseeable;
  • participation in a similar study actually or during the previous 6 months.
  • Presence of cutaneous disease on the tested area, as lesions, scars, malformations;
  • recurrent facial/labial herpes;
  • clinical and significant skin condition on the test area (e.g. active eczema, dermatitis, psoriasis etc.).
  • Diabetes
  • endocrine disease
  • hepatic disorder
  • renal disorder
  • cardiac disorder
  • pulmonary disease
  • cancer
  • neurological or psychological disease
  • inflammatory/immunosuppressive disease
  • drug allergy.
  • Anti-inflammatory drugs, anti-histaminic, topic and systemic corticosteroids, narcotic, antidepressant, immunosuppressive drugs (with the except of contraceptive or hormonal treatment starting more than 1 year ago);
  • assumption of drugs able to influence the test results in the investigator opinion.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    SUNEKOS ® 200

    The 1st intradermal treatment (T1i) was performed during the basal visit (T0), after basal evaluations planned by the study procedure and repeated after 10 (T2i), 20 (T3i) and 30 (T4i) days.

    Device: SUNEKOS ® 200

Interventions

  • DeviceSUNEKOS ® 200

    micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade

05

What researchers measure

Primary outcomes

  1. Variation of Wrinkle Severity Rating Scale (WSRS) grade

    Reduction of wrinkles severity corresponding to a decrease from the baseline of the Wrinkle Severity Rating Scale (WSRS) clinical score where: Grade 1 (absent): no visible nasolabial fold; continuous skin line. Grade 2 (mild): shallow but visible nasolabial fold with a slight indentation; minor facial feature. Grade 3 (moderate): moderately deep nasolabial folds; clear facial feature visible at normal appearance but not when stretched. Grade 4 (severe): very long and deep nasolabial folds; prominent facial feature; \<2mm visible fold when stretched. Grade 5 (very severe): extremely deep and long nasolabial fold, detrimental to facial appearance; 2-4 mm visible V-shaped fold when stretched.

    Time frame: Basal visit (T0), 10 days(T2i), 20 days (T3i), 30 days (T4i), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  2. Variation of Facial Volume Loss Scale (FVLS) grade

    Reduction of face volume loss corresponding to a decrease from the baseline of the Facial Volume Loss Scale (FVLS) where Grade 1 Mild flattening or shadowing of one or more facial regions (including the cheek, temple, preauricolar and periorbital areas). No prominent bony landmarks. No visibility of underlying musculature. Grade 2 An intermediate point between grade 1 and grade 3. Grade 3 Moderate concavity of one or more facial regions (including the cheek, temple, preauricolar and periorbital areas. Prominence of bony landmarks. May have visibility of underlying musculature. Grade 4 An intermediate point between grade 3 and grade 5. Grade 5 Severe indentation of one or more facial regions (including the cheek, temple, preauricolar and periorbital areas). Severe prominence of bony landmarks. Clear visibility of underlying musculature.

    Time frame: Basal visit (T0), 10 days(T2i), 20 days (T3i), 30 days (T4i), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

Secondary outcomes

  1. Superficial skin hydration variation

    Improvement of skin electrical capacitance value measured with Corneometer CM825 (Courage - Khazaka, Köln, Germany). The measure of the skin capacitance properties is an indirect expression of its hydration level.

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  2. Deep skin hydration variation

    Improvement of tissue dielectric constant value of superficial and deep skin layers measured with MoistureMeterD (Delfin Technologies, Kuopio - Finland)

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  3. Skin plastoelasticity variation

    Improvement of the principal torsiometric parameters Ue (immediate extensibility), Uf (final extensibility), Uv (viscoelasticity) and Ur (immediate elastic recovery).Skin firmness is measured with the instrument Dermal Torque Meter (Dia-Stron Ltd., UK).

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  4. Variation of profilometric parameters

    Reduction of the crow's feet lines profilometric parameters versus baseline where Ra is average roughness of the analysed profile, Rt is wrinkles total high, Rv is wrinkles maximum depth.

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  5. Photographic documentation (3D pictures )

    Three-dimensional pictures of the face taken by VECTRA H1 handheld imaging system.

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

  6. Face volume variation

    Face volume image analysis was carried on the 3D pictures taken by Vectra H1 thanks to Vectra analysis module (VAM) software

    Time frame: Basal visit (T0), 2 months (T2M) , 3 months (T3M), 6 months (T6M)

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03274232
Lead sponsor
Derming SRL
Responsible party
Adele Sparavigna (Medical Doctor, Derming SRL) — Principal investigator
First posted
Sep 6, 2017
Start date
Oct 27, 2016
Primary completion
Apr 25, 2017
Completion
Apr 25, 2017
Last update
Sep 6, 2017

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion